Par­ty on: Base edit­ing start­up, com­pu­ta­tion­al drug dis­cov­ery ex­perts and CRO bag close to $2B to­tal on their way to Nas­daq

On the back of Black Di­a­mond Ther­a­peu­tics’ roar­ing pub­lic de­but, the IPO mo­men­tum is push­ing three biotech play­ers from very dif­fer­ent cor­ners of the in­dus­try to shiny list­ings on the Nas­daq.

Gene edit­ing start­up Beam Ther­a­peu­tics, com­pu­ta­tion­al drug dis­cov­ery spe­cial­ist Schrödinger and con­tract re­search or­ga­ni­za­tion PPD have col­lec­tive­ly bagged close to $2 bil­lion by pric­ing at the top of or above the range laid out in their terms.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.